What is Haemonetics's payments of debt issuance costs?

Haemonetics (HAE) reported payments of debt issuance costs of $0 in Q1 2026.

What is the long-term trend for Haemonetics's payments of debt issuance costs?

Over 2 years (2023 to 2026), Haemonetics's payments of debt issuance costs has grown at a -100.0% compound annual growth rate (CAGR), from $1.12M to $0.

Haemonetics HAE Payments of Debt Issuance Costs

Payments of Debt Issuance Costs at other companies

RepligenRGEN

$0—

RevvityRVTY

——

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Haemonetics's payments of debt issuance costs?: Haemonetics (HAE) reported payments of debt issuance costs of $0 in Q1 2026.
What is the long-term trend for Haemonetics's payments of debt issuance costs?: Over 2 years (2023 to 2026), Haemonetics's payments of debt issuance costs has grown at a -100.0% compound annual growth rate (CAGR), from $1.12M to $0.